Reference
1. 김동주 기자, “만기 도래한 첨단바이오의약품 …16개 품목 중 15개 재허가”, 메디컬투데이(2021.08.31.)
Available from: http://www.mdtoday.co.kr/mdtoday/index.html?no=428698
2. 식품의약품안전처 홈페이지
Available from: https://www.mfds.go.kr/brd/m_1060/view.do?seq=14913&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
3. 홍숙 기자, “식약처, 유전성 망막 질환 유전자치료제 '럭스터나' 허가”, 헬스케어허브(2021.09.09.)
Available from: http://www.hitnews.co.kr/news/articleView.html?idxno=35834
4. 보건복지부 홈페이지
Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=2&CONT_SEQ=366888
5. 박다영 기자, 정부 “10년가 첨단바이오의약품에 5955억원 투입”,머니투데이(2021.08.25.)
Available from: https://news.mt.co.kr/mtview.php?no=2021082511445363513
6. “FDA lifts year-plus hold on Novartis' Zolgensma, setting the stage for new PhIII” Endpoints. Last modified Aug 3, 2021, Accessed Aug 5, 2021.
Available from: https://endpts.com/fda-lifts-year-plus-hold-on-novartis-zolgensma-setting-the-stage-for-new-phiii/
7. “User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act” US FDA. Last modified Aug 6, 2021, Accessed Aug 12, 2021.
Available from: https://www.fda.gov/media/113210/download
8. “Two more stem cell firms slapped with untitled letters” Regulatory Focus. Last modified Aug 10, 2021, Accessed Aug 12, 2021.
Available from: https://www.raps.org/news-and-articles/news-articles/2021/8/two-more-stem-cell-firms-slapped-with-untitled-let
9. “FDA lifts clinical hold on Rocket gene therapy trial, creating launchpad for start of pediatric dosing” Fierce. Last modified Aug 16, 2021, Accessed Aug 19, 2021.
Available from: https://www.fiercebiotech.com/biotech/fda-lifts-clinical-hold-rocket-gene-therapy-trial-creating-launchpad-for-start-pediatric
10. “PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2023 THROUGH 2027” US FDA.
Last modified Aug 23, 2021, Accessed Aug 26, 2021.
Available from: https://www.fda.gov/media/151712/download
11. “CPDUFA VII commitment letter: RWE, rare diseases see renewed attention” Regulatory Focus. Last modified Aug 23, 2021, Accessed Aug 26, 2021.
Available from: https://www.raps.org/news-and-articles/news-articles/2021/8/pduva-vii-commitment-letter-rwe-rare-diseases-see
12. “Animal models have limitations for safety assessment of gene therapies: FDA adcomm” Regulatory Focus. Last modified Sep 2, 2021, Accessed Sep 2, 2021.
Available from: https://www.raps.org/news-and-articles/news-articles/2021/9/fda-adcomm-points-to-limitations-of-animal-studies
13. “Cellular, Tissue, and Gene Therapies Advisory Committee September 2-3, 2021 Meeting Announcement” US FDA. Last modified Sep 3, 2021, Accessed Sep 3, 2021.
Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-september-2-3-2021-meeting-announcement
14. “What’s new” EMA. Last modified Aug 20. 2021, Accessed Aug 25. 2021
Available from: https://www.ema.europa.eu/documents/other/scientific-recommendations-classification-advanced-therapy-medicinal-products_en.xlsx
15. “Orphan designations-eu3192241” EMA. Last modified Aug 4. 2021, Accessed Aug. 6. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3192241
16.“Orphan designations-eu311938” EMA. Last modified Aug 6. 2021, Accessed Aug. 7. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu311938
17. “Orphan designations-eu3161715” EMA. Last modified Aug 10. 2021, Accessed Aug. 12. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161715
18. “Orphan designations-eu3182042” EMA. Last modified Aug 10. 2021, Accessed Aug. 12. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182042
19. “Orphan designations-eu312971” EMA. Last modified Aug 26. 2021, Accessed Aug. 27. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu312971
20. “Orphan designations-eu317186” EMA. Last modified Aug 25. 2021, Accessed Aug. 27. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu317186
21. “Orphan designations-eu311904” EMA. Last modified Aug 26. 2021, Accessed Aug. 28. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu311904
22. “Orphan designations-eu312983” EMA. Last modified Aug 26. 2021, Accessed Aug. 28. 2021
Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu312983
23. “Abecma” EMA. Last modified Aug 25. 2021, Accessed Aug. 27, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abecma
24. “Zolgensma” EMA. Last modified Aug 17. 2021, Accessed Aug. 19, 2021
Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
25.“PMDA 홈페이지 Available from: https://www.pmda.go.jp/files/000242808.pdf
26.“PMDA 홈페이지 Available from: https://www.pmda.go.jp/english/rs-sb-std/sb/subcommittees/0017.html
27. 김원석. (2021). 첨단바이오의약품 발전 현황 및 선진국의 치료 현황 –세포&유전자 치료제 중심, 토론회 첨단 바이오 의약품 환자접근성 어떻게 개선할 것인가?. 7월 9일. 온라인. 미간행
28. “킴리아, 암질심 상정 불발…정부가 해명해야” 청년의사. Last modified Jul 19, 2021, Accessed Aug 30, 2021.
Available from: http://www.docdocdoc.co.kr/news/articleView.html?idxno=2012669
29. “'킴리아' 암질심 문턱서 또 제동‥마음 졸이는 환자들” 메디파마뉴스. Last modified Sep 2, 2021, Accessed Sep 6, 2021.
Available from: http://medipana.com/news/news_viewer.asp?NewsNum=284469&MainKind=A&NewsKind=5&vCount=12&vKind=1
30. “[기고] '원샷' 치료제 킴리아 급여, 환자 생명이 최우선” 데일리팜. Last modified Jul 13, 2021, Accessed Aug 30, 2021.
Available from: http://www.dailypharm.com/Users/News/NewsView.html?ID=278331&REFERER=NP
31. 강혜영. (2020). 발제11 : 혁신 신약에 대한 맞춤형 급여 모형 전략: 선진외국의 제도 고찰. 한국보건행정학회 학술대회논문집, 2020(2): 1-72.
32. 한국제약협회. (2016). 특집 : 외국의 건강보험 및 보험약가제도 분석. 한국제약협회정책보고서 KPMA Brief .1. Vol.07.
33. 장선미, 한은아, 장수현, 김병철, 조혜민, 나언지, ... & 오지호. (2019). 외국약가 참조기준 개선방안 연구.
34. 배승진, 배그린, 유수연, 강현아, & 임민경. (2013). 가치에 근거한 약가제도.
35. 김동숙, 김수진, 정승연, 박주희, & 조현민. (2016). 4대 중증질환 약제 접근성 향상 방안-희귀질환치료제와 항암제 재원마련을 중심으로.
36. 조수진, 김수진, 최연미, & 이도경. (2018). 혁신 의료기술의 건강보험 보장을 위한 급여적정성평가 개선방안.
37. 건강보험심사평가원. (2020). 의약품 급여관리를 위한 실제임상근거(RWE) 플랫폼 마련 후향적 연구.
38. 변지혜. (2018). 의료기술평가 (HTA) 에 있어서 Real World data 의 활용. HIRA 정책동향, 12(1), 76-82.
39. Cheong, C., Son, K., & Bae, E. (2013). Risk sharing agreements on pharmaceuticals: lessons from foreign countries’ experience. J Health Tech Assess, 1(1), 51-60.
40. 최상은, 김성옥, 김대중, 배은미, 강대원, 신경선, & 임재옥. (2017). 제외국과의 약가수준 비교 평가 및 지침 개발 연구.
41. 김수경, 신상진, 박정수, 김준호, 백영지, 고은비, ... & 양장미. (2015). 의료기술평가제도의 국제 비교연구. 연구결과보고서, 1(1), 1-342.
42. Jørgensen, J., & Kefalas, P. (2021). The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regenerative Medicine, 16(04), 405-422.
43. Jørgensen, J., Hanna, E., & Kefalas, P. (2020). Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. Journal of market access & health policy, 8(1), 1715536.
44. 서울대학교 산학협력단. (2017). 약제비 총액관리제 도입 방안.
45. 변지혜. (2019). 약품비 사후관리를 위한 주요국의 제네릭 약가 제도 동향.
46. 박은자, 이상원, 손경복, 조혜경, 유명순, 하솔잎, ... & 최유은. (2019). 기술 변화에 따른 의약품의 미래 전망과 중장기 보건정책 및 거버넌스 연구.
47. 박실비아. (2017). 고가 신약의 효과적 급여 관리를 위한 해외 동향과 시사점. 보건·복지 Issue & Focus 342호, 1-4.
48. 한국제약협회. (2016). 영국의 건강보험 체계 및 약가제도. 한국제약협회정책보고서. 12 Vol. 10.
49. 이영성. (2018). 우리나라 보건의료 발전을 위한 의료기술평가의 역할. 보건행정학회지, 28(3), 263-271.
50. Cheong, C., Son, K., & Bae, E. (2013). Risk sharing agreements on pharmaceuticals: lessons from foreign countries’ experience. J Health Tech Assess, 1(1), 51-60.
51. 한국제약협회. (2016). 미국의 건강보험 체계 및 약가제도. 한국제약협회정책보고서. 12 Vol.